Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide

被引:19
作者
Gault, VA [1 ]
Harriott, P
Flatt, PR
O'Harte, FPM
机构
[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland
[2] Queens Univ Belfast, Ctr Med Biol, Sch Biol & Biochem, Belfast BT9 7BL, Antrim, North Ireland
关键词
bioactive domains; BRIN-BD11; cells; cAMP; GIP; insulin secretion;
D O I
10.1023/A:1022073819618
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthetic fragment peptides of glucose-dependent insulinotropic polypeptide (GIP) were evaluated for their ability to elevate cellular cAMP production and stimulate insulin secretion. In GIP receptor transfected CHL cells, GIP(4-42) and GIP(17-30) dose-dependently inhibited GIP-stimulated cAMP production (40 +/- 8%; p < 0.01 and 15 +/- 6%; p < 0.05, respectively), while GIP(1-16) exerted very weak agonist effects on cAMP production. In the clonal pancreatic beta-cell line, BRIN-BD11, GIP(1-16) demonstrated weak insulin releasing activity compared with native GIP. In contrast, GIP(4-42) and GIP (17-30) weakly antagonized the insulin releasing activity of the native peptide (23 +/- 6%; p < 0.05 and 11 +/- 3%, respectively). These data demonstrate the critical role of the N-terminus and the involvement of regions of the C-terminal domain in generating full biological potency of GIP.
引用
收藏
页码:523 / 528
页数:6
相关论文
共 13 条
[1]   ACTIONS OF GIP [J].
BROWN, JC ;
DAHL, M ;
KWAUK, S ;
MCINTOSH, CHS ;
OTTE, SC ;
PEDERSON, RA .
PEPTIDES, 1981, 2 :241-245
[2]   The entero-insular axis in type 2 diabetes - incretins as therapeutic agents [J].
Creutzfeldt, W .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2001, 109 :S288-S303
[3]   Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs [J].
Deacon, CF ;
Danielson, P ;
Klarskov, L ;
Olesen, M ;
Holst, JJ .
DIABETES, 2001, 50 (07) :1588-1597
[4]  
Flatt PR, 2001, DIABETOLOGIA, V44, pA195
[5]   Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide [J].
Gault, VA ;
O'Harte, FPM ;
Harriott, P ;
Flatt, PR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (05) :1420-1426
[6]   CLONING, FUNCTIONAL EXPRESSION, AND CHROMOSOMAL LOCALIZATION OF THE HUMAN PANCREATIC-ISLET GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR [J].
GREMLICH, S ;
PORRET, A ;
HANI, EH ;
CHERIF, D ;
VIONNET, N ;
FROGUEL, P ;
THORENS, B .
DIABETES, 1995, 44 (10) :1202-1208
[7]   Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP) [J].
Hinke, SA ;
Manhart, S ;
Pamir, N ;
Demuth, HU ;
Gelling, RW ;
Pederson, RA ;
McIntosh, CHS .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2001, 1547 (01) :143-155
[8]  
MALETTI M, 1986, PEPTIDES, V7, P75, DOI 10.1016/0196-9781(86)90167-1
[9]   Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion [J].
McClenaghan, NH ;
Barnett, CR ;
AhSing, E ;
AbdelWahab, YH ;
OHarte, FPM ;
Yoon, TW ;
SwanstonFlatt, SK ;
Flatt, PR .
DIABETES, 1996, 45 (08) :1132-1140
[10]   The metabolic role of GIP: Physiology and pathology [J].
Morgan, LM .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (02) :585-591